• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心房颤动与慢性完全闭塞经皮冠状动脉介入治疗结局:来自 Progress-CTO 注册研究的观察。

Atrial fibrillation and chronic total occlusion percutaneous coronary intervention outcomes: insights from the Progress-CTO registry.

机构信息

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.

Texas Health Presbyterian Hospital, Dallas, TX, USA.

出版信息

J Invasive Cardiol. 2023 Aug;35(8). doi: 10.25270/jic/23.00114.

DOI:10.25270/jic/23.00114
PMID:37983099
Abstract

BACKGROUND

We examined the effect of atrial fibrillation on the outcomes of chronic total occlusion (CTO) percutaneous coronary intervention (PCI).

METHODS

We examined the baseline characteristics and procedural outcomes of 9,166 CTO PCIs performed at 39 US and non-US centers between 2012 and 2023.

RESULTS

Atrial fibrillation was present in 1122 (12%) patients. These patients were older and had a higher incidence of comorbidities, such as hypertension, dyslipidemia, heart failure, cerebrovascular disease, and peripheral arterial disease, lower left ventricular ejection fraction, and lower eGFR. Their CTOs were more likely to have moderate to severe calcification and longer lesion length. They also had higher mean J-CTO and PROGRESS-CTO complications (Acute MI, MACE, Mortality, Perforation, and Pericardiocentesis) scores. Patients with atrial fibrillation had higher prevalence of uncrossable and undilatable CTO lesions and required longer procedure (107 vs 119 min; P less than .001) and fluoroscopy (40 vs 43 min; P=.005) time. Technical success and MACE, including procedural/in-hospital bleeding, were similar in patients with and without atrial fibrillation. Although the crude incidence of MACE on follow-up (median 61 days) was significantly higher in patients with atrial fibrillation, the latter was not independently associated with adverse events on Cox proportional hazards analysis.

CONCLUSIONS

Patients with atrial fibrillation undergoing CTO PCI are older, have more comorbidities, higher lesion complexity, and longer procedure time, but similar technical success and in-hospital MACE. They have higher MACE and mortality during follow-up, but the difference is not significant after adjusting for potential confounding variables.

摘要

背景

我们研究了心房颤动对慢性完全闭塞(CTO)经皮冠状动脉介入治疗(PCI)结局的影响。

方法

我们检查了 2012 年至 2023 年期间在 39 个美国和非美国中心进行的 9166 例 CTO PCI 的基线特征和手术结果。

结果

1122 例(12%)患者存在心房颤动。这些患者年龄较大,合并症发生率较高,如高血压、血脂异常、心力衰竭、脑血管疾病和外周动脉疾病,左心室射血分数较低,eGFR 较低。他们的 CTO 更有可能存在中度至重度钙化和较长的病变长度。他们的 J-CTO 和 PROGRESS-CTO 并发症(急性心肌梗死、MACE、死亡率、穿孔和心包穿刺)评分也较高。心房颤动患者的不可交叉和不可扩张性 CTO 病变的发生率较高,需要更长的手术(107 分钟比 119 分钟;P 小于 0.001)和透视时间(40 分钟比 43 分钟;P 等于 0.005)。有和没有心房颤动的患者的技术成功率和 MACE(包括手术/住院期间出血)相似。尽管在随访期间(中位数 61 天)有心房颤动的患者的 MACE 发生率明显较高,但在 Cox 比例风险分析中,后者与不良事件无关。

结论

接受 CTO PCI 的心房颤动患者年龄较大,合并症较多,病变复杂性较高,手术时间较长,但技术成功率和住院期间的 MACE 相似。他们在随访期间的 MACE 和死亡率较高,但在调整潜在混杂变量后差异无统计学意义。

相似文献

1
Atrial fibrillation and chronic total occlusion percutaneous coronary intervention outcomes: insights from the Progress-CTO registry.心房颤动与慢性完全闭塞经皮冠状动脉介入治疗结局:来自 Progress-CTO 注册研究的观察。
J Invasive Cardiol. 2023 Aug;35(8). doi: 10.25270/jic/23.00114.
2
Predicting Periprocedural Complications in Chronic Total Occlusion Percutaneous Coronary Intervention: The PROGRESS-CTO Complication Scores.预测慢性完全闭塞性经皮冠状动脉介入治疗围手术期并发症:PROGRESS-CTO并发症评分
JACC Cardiovasc Interv. 2022 Jul 25;15(14):1413-1422. doi: 10.1016/j.jcin.2022.06.007.
3
Geographic diversity in chronic total occlusion percutaneous coronary intervention: insights from the PROGRESS-CTO registry.慢性完全闭塞经皮冠状动脉介入治疗的地域差异:来自 PROGRESS-CTO 注册研究的见解。
J Invasive Cardiol. 2024 Sep;36(9). doi: 10.25270/jic/24.00056.
4
Lesion complexity and procedural outcomes associated with ostial chronic total occlusions: Insights from the PROGRESS-CTO Registry.病变复杂性与开口部慢性完全闭塞介入治疗结果的相关性:来自 PROGRESS-CTO 注册研究的见解。
J Invasive Cardiol. 2023 Dec;35(12). doi: 10.25270/jic/23.00034.
5
A Systematic Review of Periprocedural Risk Prediction Scores in Chronic Total Occlusion Percutaneous Coronary Intervention.慢性完全闭塞经皮冠状动脉介入治疗围手术期风险预测评分的系统评价
Am J Cardiol. 2023 Apr 15;193:118-125. doi: 10.1016/j.amjcard.2023.01.044. Epub 2023 Mar 9.
6
Prevalence and outcomes of balloon undilatable chronic total occlusions: Insights from the PROGRESS-CTO.球囊无法扩张的慢性完全闭塞病变的患病率和结局:来自 PROGRESS-CTO 的观察。
Int J Cardiol. 2022 Sep 1;362:42-46. doi: 10.1016/j.ijcard.2022.04.057. Epub 2022 Apr 26.
7
Gender differences in chronic total occlusion percutaneous coronary interventions: Insights from the PROGRESS-CTO registry.性别差异在慢性完全闭塞经皮冠状动脉介入治疗中的作用:来自 PROGRESS-CTO 注册研究的启示。
Catheter Cardiovasc Interv. 2022 Nov;100(6):1010-1018. doi: 10.1002/ccd.30425. Epub 2022 Oct 25.
8
Impact of preprocedural anemia on in-hospital and follow-up outcomes of chronic total occlusion percutaneous coronary intervention.
Catheter Cardiovasc Interv. 2023 Nov;102(5):857-863. doi: 10.1002/ccd.30810. Epub 2023 Sep 8.
9
Impact of lesion length on the outcomes of chronic total occlusion percutaneous coronary intervention: Insights from the PROGRESS-CTO registry.病变长度对慢性完全闭塞性经皮冠状动脉介入治疗结果的影响:来自PROGRESS-CTO注册研究的见解。
Catheter Cardiovasc Interv. 2023 Mar;101(4):747-755. doi: 10.1002/ccd.30581. Epub 2023 Feb 5.
10
Outcomes of Patients With Acute Coronary Syndromes Undergoing Chronic Total Occlusion Percutaneous Coronary Intervention.接受慢性完全闭塞经皮冠状动脉介入治疗的急性冠状动脉综合征患者的预后
J Invasive Cardiol. 2023 Jan;35(1):E24-E30. doi: 10.25270/jic/22.00258. Epub 2022 Dec 15.

引用本文的文献

1
The Prevalence and Impact of Atrial Fibrillation on Patients with Chronic Total Occlusions: Insights from the National Inpatient Sample.心房颤动在慢性完全闭塞患者中的患病率及影响:来自全国住院患者样本的见解
J Cardiovasc Dev Dis. 2025 Mar 14;12(3):100. doi: 10.3390/jcdd12030100.